Other grades of this product :
| 4-[5-(4-Butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinehydrochloride Basic information |
| 4-[5-(4-Butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinehydrochloride Chemical Properties |
| storage temp. | -20°C | | solubility | DMSO: >10mg/mL | | form | powder | | color | white to off-white |
| 4-[5-(4-Butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinehydrochloride Usage And Synthesis |
| Biochem/physiol Actions | PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production. |
| 4-[5-(4-Butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinehydrochloride Preparation Products And Raw materials |
|
![4-[5-(4-Butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinehydrochloride](/img/388575-52-8.jpg "4-[5-(4-Butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinehydrochloride")
日本语
한국어
Français
Deutsch
España
Türkiye